stoxline Quote Chart Rank Option Currency Glossary
AnaptysBio, Inc. (ANAB)
30.37  0.05 (0.16%)    07-12 13:23
Open: 30.52
High: 31.52
Volume: 87,232
Pre. Close: 30.32
Low: 29.99
Market Cap: 830(M)
Technical analysis
2024-07-12 12:48:30 PM
Short term     
Mid term     
Targets 6-month :  36.81 1-year :  43
Resists First :  31.52 Second :  36.81
Pivot price 25.55
Supports First :  25.79 Second :  22.26
MAs MA(5) :  27.81 MA(20) :  25.02
MA(100) :  23.85 MA(250) :  21.03
MACD MACD :  1.1 Signal :  0.5
%K %D K(14,3) :  93.2 D(3) :  94.4
RSI RSI(14): 77.2
52-week High :  31.52 Low :  13.35
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ANAB ] has closed above the upper band by 7.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 71% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 30.66 - 30.76 30.76 - 30.86
Low: 26.79 - 26.92 26.92 - 27.03
Close: 30.1 - 30.29 30.29 - 30.47
Company Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Headline News

Thu, 11 Jul 2024
AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High at $28.24 - MarketBeat

Wed, 10 Jul 2024
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year? - Yahoo Canada Shine On

Mon, 08 Jul 2024
AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade) (NASDAQ:ANAB) - Seeking Alpha

Fri, 05 Jul 2024
AnaptysBio (NASDAQ:ANAB) Shares Gap Up to $23.94 - Defense World

Wed, 03 Jul 2024
AnaptysBio (NASDAQ:ANAB) Shares Gap Up to $23.94 - MarketBeat

Sat, 29 Jun 2024
Head to Head Review: AnaptysBio (NASDAQ:ANAB) and Oncolytics Biotech (NASDAQ:ONCY) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 27 (M)
Shares Float 17 (M)
Held by Insiders 1.9 (%)
Held by Institutions 111.4 (%)
Shares Short 4,620 (K)
Shares Short P.Month 4,440 (K)
Stock Financials
EPS -6.14
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.75
Profit Margin 0 %
Operating Margin -587.9 %
Return on Assets (ttm) -20.3 %
Return on Equity (ttm) -136.8 %
Qtrly Rev. Growth 422.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.84
EBITDA (p.s.) -5.65
Qtrly Earnings Growth 0 %
Operating Cash Flow -133 (M)
Levered Free Cash Flow -89 (M)
Stock Valuations
PE Ratio -4.93
PEG Ratio 0
Price to Book value 17.26
Price to Sales 35.95
Price to Cash Flow -6.19
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android